Human lipoxygenases (LOXs) are a family of iron-containing enzymes involved in catalyzing the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (HETE) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation. Platelet-type 12-(S)-LOX (12-LOX) is of particular interest because of its demonstrated role in skin diseases, diabetes, platelet hemostasis, thrombosis, and cancer. Disclosed herein is the identification and medicinal chemistry optimization of a 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide-based scaffold. The compounds display nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases. In addition to possessing favorable ADME properties, the compounds also inhibit PAR-4 induced aggregation and calcium mobilization in human platelets, and reduce 12-HETE in mouse/human beta cells. The compounds can also be used in methods for treating or preventing a 12-lipoxygenase mediated disease or disorder.
人类脂
氧合酶(LOXs)是一个含
铁酶家族,参与催化多不饱和
脂肪酸的
氧化,以提供相应的具有
生物活性的羟基
二十碳四烯酸(HETE)代谢物。这些类二十
碳烷烃信号分子参与了许多生理反应,如血小板聚集、炎症和细胞增殖。血小板型 12-(S)-LOX(12-LOX)尤其令人感兴趣,因为它在皮肤病、糖尿病、血小板止血、血栓形成和癌症中的作用已得到证实。本文公开了 4-((2-羟基-3-甲
氧基
苄基)
氨基)
苯磺
酰胺基支架的鉴定和药物
化学优化。这些化合物对 12-LOX 具有 nM 效能,对相关脂
氧合酶和环
氧合酶具有极佳的选择性。除了具有良好的 A
DME 特性外,这些化合物还能抑制
PAR-4 诱导的人血小板聚集和
钙动员,并减少小鼠/人 beta 细胞中的 12-HETE。这些化合物还可用于治疗或预防 12-脂
氧合酶介导的疾病或紊乱。